Company / R&D Expense
Repligen R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$54.2M
FY2025
5-year range
$34.3M / $54.2M
FY2021-FY2025
Trend
+25.4%
vs FY2024
Sector context
#177 of 210
Health Care
What the data says
Repligen's r&d expense of $54M is lower than 84% of companies in the Health Care sector (FY2025). Improved from $43M to $54M over the past 2 years.
Based on SEC 10-K filings.
$54M in FY2025 with a 5-year CAGR of +21.8%.
Improved from $43M to $54M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +7.2%
- 5-Year CAGR
- +21.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 210This company $54.2M Sector average $644.0M
▼
-91.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.8%, indicating consistent growth.
- In FY2025, r&d expense increased 25.4% year-over-year.
- Ranks #177 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Negative profit margin: -18.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $54.2M | +25.4% |
| FY2024 | $43.2M | +1.1% |
| FY2023 | $42.7M | -2.8% |
| FY2022 | $43.9M | +28.2% |
| FY2021 | $34.3M | +69.8% |
| FY2020 | $20.2M | +3.8% |
| FY2019 | $19.4M | +22.9% |
| FY2018 | $15.8M | +82.4% |
| FY2017 | $8.7M | +17.9% |
| FY2016 | $7.4M | +0.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026